- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–19
of 19
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Arterial Hypertension, Healthy
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- HIV
- Interventions
- MRI, L-NMMA, Acetylcholine
- Procedure · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Secondary Pulmonary Arterial Hypertension
- Interventions
- Heart Catheterization
- Procedure
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Elafin, Placebo
- Drug
- Lead sponsor
- Roham T. Zamanian
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hypertension, Pulmonary, Pulmonary Arterial Hypertension
- Interventions
- Treprostinil diethanolamine, Esomeprazole
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
- Interventions
- Hyperpolarized Xe129
- Drug
- Lead sponsor
- Mario Castro, MD, MPH
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sodium Nitrite Inhalation Solution, Placebo and AIR001 Inhalation Solution (Expansion arm)
- Drug
- Lead sponsor
- Aires Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- High Altitude Pulmonary Hypertension
- Interventions
- Aminophylline, Ambrisentan, Aminophylline plus ambrisentan
- Drug
- Lead sponsor
- Thies Schroeder
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil Inhalation Powder
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System, Placebo Solution
- Drug · Device · Other
- Lead sponsor
- Pharmosa Biopharm Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Hypertension, Pulmonary, Pulmonary Arterial Hypertension
- Interventions
- Treprostinil diethanolamine, Standardized meals
- Drug · Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 150 participants
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Healthy Volunteers, Pulmonary Arterial Hypertension
- Interventions
- LTP, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Orange, California • Stanford, California + 16 more
- Conditions
- Pulmonary Arterial Hypertension PAH
- Interventions
- Placebo Cohort 1 (1.5 mg/kg/dose) only, ZMA001 (BC-NKA-20008)
- Other · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Interventions
- 15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution
- Drug
- Lead sponsor
- Aires Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 56 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- KAR5585 Capsules, Placebo Capsules
- Drug
- Lead sponsor
- Karos Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin